Effective tranexamic acid concentration for 95% inhibition of tissue-type plasminogen activator induced hyperfibrinolysis in children with congenital heart disease

2015 ◽  
Vol 32 (12) ◽  
pp. 844-850 ◽  
Author(s):  
Laurence Rozen ◽  
David Faraoni ◽  
Cristel Sanchez Torres ◽  
Ariane Willems ◽  
Denis C.F. Noubouossie ◽  
...  
Keyword(s):  
Congenital Heart Disease ◽  
Heart Disease ◽  
Tranexamic Acid ◽  
Plasminogen Activator ◽  
Acid Concentration ◽  
Congenital Heart ◽  
Tissue Type ◽  
Tissue Type Plasminogen Activator ◽  
Type Plasminogen Activator

In Vitro Simulation of Thrombolysis Inhibition

2008 ◽  
Vol 14 (2) ◽  
pp. 234-237
Author(s):  
Thomas W. Stief
Keyword(s):  
Tranexamic Acid ◽  
Plasminogen Activator ◽  
Microtiter Plate ◽  
Caproic Acid ◽  
Tissue Type ◽  
Clot Lysis ◽  
Tissue Type Plasminogen Activator ◽  
Type Plasminogen Activator ◽  
In Vitro Simulation

Hyperfibrinolysis is a serious clinical complication. The inhibitory concentrations 50% of antifibrinolytics were analyzed in the microtiter plate clot lysis assay, using 50 µL of plasma clots, 10 µL of antifibrinolytic drug, 10 µL of 354 IU/mL (final) urokinase, 4.46 µg/mL (final) tissue-type plasminogen activator or 0.6 mg/mL plasmin, and 50 µL of pooled normal plasma as clot supernatant. The inhibitory concentrations 50% of lysine against urokinase or tissue-type plasminogen activator is 2.0 or 4.2 mM, against ε-amino-caproic acid 0.7 or 1.5 mM, against tranexamic acid 0.03 or 0.17 mM, respectively. The inhibitory concentrations 50% of lysine, ε-amino-caproic acid, or tranexamic acid against plasmin is 7.4, 0.4, or 0.04 mM. The inhibitory concentrations 50% of aprotinin against urokinase or tissue-type plasminogen activator is about 60 KIU/mL, against plasmin 19 KIU/mL. Lysine might be a new antifibrinolytic drug with a clinically interesting rapid pharmacokinetic. This data help correct dosing of antifibrinolytics to patients with hyperfibrinolysis.

scholarly journals Endothelial Tissue-Type Plasminogen Activator Release in Coronary Heart Disease

1998 ◽  
Vol 31 (3) ◽  
pp. 547-551 ◽  
Author(s):  
Hans Martin Hoffmeister ◽  
Michael Jur ◽  
Monika Ruf-Lehmann ◽  
Uwe Helber ◽  
Wolfgang Heller ◽  
...  
Keyword(s):  
Coronary Heart Disease ◽  
Heart Disease ◽  
Plasminogen Activator ◽  
Tissue Type ◽  
Tissue Type Plasminogen Activator ◽  
Type Plasminogen Activator ◽  
Endothelial Tissue

Purification and efficient refolding process for recombinant tissue-type plasminogen activator derivative (reteplase) using glycerol and Tranexamic acid

2017 ◽  
Vol 53 ◽  
pp. 135-144 ◽  
Author(s):  
Seyed Babak Mousavi ◽  
Ahmad Fazeli ◽  
Seyed Abbas Shojaosadati ◽  
Mohammad Reza Fazeli ◽  
Sameereh Hashemi-Najafabadi
Keyword(s):  
Tranexamic Acid ◽  
Plasminogen Activator ◽  
Tissue Type ◽  
Tissue Type Plasminogen Activator ◽  
Type Plasminogen Activator
Sign in / Sign up

Export Citation Format

Share Document